WO2010019952A3 - Methods and systems for predicting response of cells to a therapeutic agent - Google Patents
Methods and systems for predicting response of cells to a therapeutic agent Download PDFInfo
- Publication number
- WO2010019952A3 WO2010019952A3 PCT/US2009/054051 US2009054051W WO2010019952A3 WO 2010019952 A3 WO2010019952 A3 WO 2010019952A3 US 2009054051 W US2009054051 W US 2009054051W WO 2010019952 A3 WO2010019952 A3 WO 2010019952A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- methods
- nas
- treatment
- therapeutic agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 3
- 230000004044 response Effects 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 5
- 230000001413 cellular effect Effects 0.000 abstract 3
- 230000004043 responsiveness Effects 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 238000007635 classification algorithm Methods 0.000 abstract 1
- 238000005094 computer simulation Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020117005954A KR20110044905A (en) | 2008-08-15 | 2009-08-17 | Methods and systems for predicting cell response to therapeutic agents |
MX2011001764A MX2011001764A (en) | 2008-08-15 | 2009-08-17 | Methods and systems for predicting response of cells to a therapeutic agent. |
US13/058,687 US8623592B2 (en) | 2008-08-15 | 2009-08-17 | Methods and systems for predicting response of cells to a therapeutic agent |
ES09791584T ES2433424T3 (en) | 2008-08-15 | 2009-08-17 | Methods and systems to predict cell response to a therapeutic agent |
BRPI0917871A BRPI0917871A2 (en) | 2008-08-15 | 2009-08-17 | anti-erbb3 therapeutic agent for use in tumor therapy, methods for predicting tumor responsiveness of an anti-erbb3 therapeutic agent, for selecting anti-erbb3 therapy for a patient, for predicting cell response to treatment with a therapeutic agent , to identify a biomarker, and to prevent administration of an anti-erbb3 cancer drug, and kit to predict cell response to treatment with a therapeutic agent |
UAA201101792A UA104868C2 (en) | 2008-08-15 | 2009-08-17 | Method for treating patient having neoplastic tumor according to predicted reaction |
EP09791584.7A EP2318548B1 (en) | 2008-08-15 | 2009-08-17 | Methods and systems for predicting response of cells to a therapeutic agent |
JP2011523216A JP2012500008A (en) | 2008-08-15 | 2009-08-17 | Methods and systems for predicting cellular responses to therapeutic agents |
AU2009281721A AU2009281721A1 (en) | 2008-08-15 | 2009-08-17 | Methods and systems for predicting response of cells to a therapeutic agent |
EA201100373A EA022884B1 (en) | 2008-08-15 | 2009-08-17 | METHOD FOR TREATING NEOPLASTIC TUMOR USING ANTI-ErbB3 ANTIBODY |
NZ591137A NZ591137A (en) | 2008-08-15 | 2009-08-17 | Methods and systems for predicting response of cells to a therapeutic agent |
CA2732658A CA2732658A1 (en) | 2008-08-15 | 2009-08-17 | Methods and systems for predicting response of cells to a therapeutic agent |
CN2009801404673A CN102224255A (en) | 2008-08-15 | 2009-08-17 | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
US12/707,521 US20110027291A1 (en) | 2008-08-15 | 2010-02-17 | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
IL210865A IL210865A (en) | 2008-08-15 | 2011-01-25 | Anti-erbb3 antibody for use in a method for treating a patient having a neoplastic tumor |
ZA2011/00921A ZA201100921B (en) | 2008-08-15 | 2011-02-04 | Methods and systems for predicting response of cells to a therapeutic agent |
TN2011000069A TN2011000069A1 (en) | 2009-08-17 | 2011-02-11 | Methods and systems for preicting response of cells to a therapeutic agent |
MA33695A MA32630B1 (en) | 2008-08-15 | 2011-03-11 | Methods, systems and products to predict the response of cancer cells to a therapeutic agent, and treatment to a patient according to the expected response |
HK11109930.1A HK1155782A1 (en) | 2008-08-15 | 2011-09-21 | Methods and systems for predicting response of cells to a therapeutic agent |
US14/148,379 US20140127238A1 (en) | 2008-08-15 | 2014-01-06 | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
US15/384,664 US20170307631A1 (en) | 2008-08-15 | 2016-12-20 | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18905308P | 2008-08-15 | 2008-08-15 | |
US61/189,053 | 2008-08-15 | ||
US19470208P | 2008-09-30 | 2008-09-30 | |
US61/194,702 | 2008-09-30 | ||
US20820609P | 2009-02-20 | 2009-02-20 | |
US61/208,206 | 2009-02-20 | ||
US17036709P | 2009-04-17 | 2009-04-17 | |
US61/170,367 | 2009-04-17 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/058,687 A-371-Of-International US8623592B2 (en) | 2008-08-15 | 2009-08-17 | Methods and systems for predicting response of cells to a therapeutic agent |
US12/707,521 Continuation-In-Part US20110027291A1 (en) | 2008-08-15 | 2010-02-17 | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
US14/148,379 Continuation US20140127238A1 (en) | 2008-08-15 | 2014-01-06 | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010019952A2 WO2010019952A2 (en) | 2010-02-18 |
WO2010019952A3 true WO2010019952A3 (en) | 2010-06-24 |
Family
ID=41228727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/054051 WO2010019952A2 (en) | 2008-08-15 | 2009-08-17 | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
Country Status (24)
Country | Link |
---|---|
US (4) | US8623592B2 (en) |
EP (1) | EP2318548B1 (en) |
JP (1) | JP2012500008A (en) |
KR (1) | KR20110044905A (en) |
CN (1) | CN102224255A (en) |
AU (1) | AU2009281721A1 (en) |
BR (1) | BRPI0917871A2 (en) |
CA (1) | CA2732658A1 (en) |
CO (1) | CO6341654A2 (en) |
CR (1) | CR20110128A (en) |
DO (1) | DOP2011000054A (en) |
EA (1) | EA022884B1 (en) |
EC (1) | ECSP11010872A (en) |
ES (1) | ES2433424T3 (en) |
HK (1) | HK1155782A1 (en) |
IL (1) | IL210865A (en) |
MA (1) | MA32630B1 (en) |
MX (1) | MX2011001764A (en) |
NZ (1) | NZ591137A (en) |
PE (1) | PE20120015A1 (en) |
SV (1) | SV2011003840A (en) |
UA (1) | UA104868C2 (en) |
WO (1) | WO2010019952A2 (en) |
ZA (1) | ZA201100921B (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2129396T1 (en) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
US8623592B2 (en) | 2008-08-15 | 2014-01-07 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
US8927694B2 (en) * | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
HUE029026T2 (en) | 2009-12-22 | 2017-01-30 | Roche Glycart Ag | ANTI-HER3 Antibodies and uses thereof |
PL2544680T3 (en) * | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative breast cancer |
US20110318336A1 (en) * | 2010-03-29 | 2011-12-29 | George Mason Intellectual Properties, Inc. | Identification and Treatment of Aggressive Lung Cancer Tumors |
SG185366A1 (en) | 2010-05-04 | 2012-12-28 | Merrimack Pharmaceuticals Inc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
WO2011159904A1 (en) * | 2010-06-17 | 2011-12-22 | The Trustees Of The University Of Pennsylvania | Methods for predicting cellular signaling responses to combinatorial stimuli |
TW201302793A (en) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | Novel antigen binding proteins |
EP2635604B1 (en) | 2010-11-01 | 2016-11-30 | Symphogen A/S | Pan-her antibody composition |
SG193006A1 (en) | 2011-03-02 | 2013-10-30 | Berg Llc | Interrogatory cell-based assays and uses thereof |
EA201300996A1 (en) | 2011-03-11 | 2014-01-30 | Мерримак Фармасьютикалс, Инк. | USE OF EGFR FAMILY RECEPTOR INHIBITORS IN THE TREATMENT OF THE BREAST-GROWTH CANCER |
JP5588086B2 (en) | 2011-04-19 | 2014-09-10 | メリマック ファーマシューティカルズ インコーポレーティッド | Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies |
US8691231B2 (en) * | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
EP2530462A1 (en) * | 2011-06-03 | 2012-12-05 | Merrimack Pharmaceuticals, Inc. | Methods and kits for predicting tumor responses to antibodies against epidermal growth factor receptor (EGFR) and uses thereof |
AU2012294326A1 (en) * | 2011-08-10 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
MX357391B (en) * | 2011-09-30 | 2018-07-06 | Regeneron Pharma | Anti-erbb3 antibodies and uses thereof. |
CN103959065B (en) * | 2011-10-06 | 2018-07-17 | Aveo制药公司 | Predict the response of tumour confrontation ERBB3 antibody |
AU2012335543C1 (en) | 2011-11-09 | 2017-12-14 | Beijing Cotimes Biotech Co., Ltd., | HER3 antibodies and uses thereof |
CN104160400A (en) * | 2011-12-16 | 2014-11-19 | 克里帝奥成果技术公司 | Programmable cell model for determining cancer treatments |
CN108048521B (en) * | 2012-04-02 | 2022-05-27 | 博格有限责任公司 | Interrogative cell-based assays and uses thereof |
EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
CA2876636C (en) * | 2012-06-13 | 2022-09-13 | Medimmune, Llc | Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies |
KR101430309B1 (en) * | 2012-11-14 | 2014-08-13 | 이선우 | Bio 3D Modeling Device. |
ES2971536T3 (en) * | 2012-11-21 | 2024-06-05 | Janssen Biotech Inc | egfr/c-met bispecific antibodies |
US10489717B2 (en) | 2013-01-03 | 2019-11-26 | Aetna, Inc. | System and method for pharmacovigilance |
US11424040B2 (en) * | 2013-01-03 | 2022-08-23 | Aetna Inc. | System and method for pharmacovigilance |
AR094403A1 (en) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | ANTI-HER3 ANTIBODY COMBINATION THERAPY |
KR20140093347A (en) * | 2013-01-15 | 2014-07-28 | 삼성전자주식회사 | Genes inducing agonistic effects by anti-c-Met antibody treatment and drug method using thereof |
JP2016535079A (en) * | 2013-09-30 | 2016-11-10 | 第一三共株式会社 | Nucleic acid biomarkers and uses thereof |
WO2015048804A2 (en) * | 2013-09-30 | 2015-04-02 | Daiichi Sankyo Co., Ltd. | Protein biomarker and uses thereof |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
KR102456088B1 (en) | 2014-04-04 | 2022-10-19 | 델 마 파마슈티컬스 | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
US20150285817A1 (en) * | 2014-04-08 | 2015-10-08 | Biodesix, Inc. | Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy |
MA39599A (en) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage and administration anti-egfr therapeutics |
US10482385B2 (en) | 2014-09-11 | 2019-11-19 | Berg Llc | Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
CN107750165A (en) * | 2015-04-17 | 2018-03-02 | 梅里麦克制药股份有限公司 | By the combined therapy of class's soil monoclonal antibody in plug |
GB201508841D0 (en) * | 2015-05-22 | 2015-07-01 | Isis Innovation | Treatment |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
JP6382459B1 (en) * | 2015-06-15 | 2018-08-29 | ナントミクス,エルエルシー | System and method for patient specific prediction of drug response from cell line genomics |
JP6836586B2 (en) * | 2015-09-29 | 2021-03-03 | エイチティージー モレキュラー ダイアグノスティクス, インコーポレイテッド | Methods for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL) |
EP3429623A1 (en) | 2016-03-15 | 2019-01-23 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
EP3542290B1 (en) * | 2016-11-17 | 2024-01-03 | NantBio, Inc. | Validation of inferred anticancer pathways |
JP7404648B2 (en) | 2019-04-25 | 2023-12-26 | 富士通株式会社 | Therapeutic drug presentation method, therapeutic drug presentation device, and therapeutic drug presentation program |
US20230088271A1 (en) * | 2020-02-28 | 2023-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and Methods for Determining Spatial Accumulation of Signaling Molecules Within Tissue Samples |
WO2021240263A1 (en) | 2020-05-26 | 2021-12-02 | Insilico Medicine Ip Limited | Biological data signatures of aging and methods of determining a biological aging clock |
WO2022058980A1 (en) | 2020-09-21 | 2022-03-24 | Insilico Medicine Ip Limited | Methylation data signatures of aging and methods of determining a methylation aging clock |
CN113049249A (en) * | 2020-12-31 | 2021-06-29 | 山东科技大学 | Motor bearing fault diagnosis method and system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997035885A1 (en) * | 1996-03-27 | 1997-10-02 | Genentech, Inc. | ErbB3 ANTIBODIES |
WO2007015935A2 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
WO2008100624A2 (en) * | 2007-02-16 | 2008-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5344760A (en) * | 1991-06-03 | 1994-09-06 | Ciba Corning Diagnostics Corp. | Method of cancer detection |
US6983227B1 (en) * | 1995-01-17 | 2006-01-03 | Intertech Ventures, Ltd. | Virtual models of complex systems |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
CN1202247C (en) * | 1996-07-12 | 2005-05-18 | 基因技术股份有限公司 | Chimeric heteromultimer adhesins |
US6255455B1 (en) * | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
US20020002276A1 (en) * | 1997-02-10 | 2002-01-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
GB2336695A (en) | 1998-04-20 | 1999-10-27 | Teamware Group Oy | Modelling a work process |
JP2002515511A (en) | 1998-05-15 | 2002-05-28 | イムクローン システムズ インコーポレイティド | Treatment of human tumors using inhibitors of radiation and growth factor receptor tyrosine kinase |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
PL202369B1 (en) * | 1999-08-27 | 2009-06-30 | Genentech Inc | DOSAGES FOR TREATMENT WITH ANTI−ErbB2 ANTIBODIES |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
DE60139768D1 (en) * | 2000-05-19 | 2009-10-15 | Genentech Inc | GENERAL PROCESS FOR IMPROVING THE PROBABILITY OF AN EFFECTIVE RESPONSE TO A K |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US6871171B1 (en) * | 2000-10-19 | 2005-03-22 | Optimata Ltd. | System and methods for optimized drug delivery and progression of diseased and normal cells |
EP1228766A1 (en) * | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
WO2003011897A1 (en) * | 2001-07-27 | 2003-02-13 | The Regents Of The University Of California | Modulation of heregulin and her3 interaction |
US7662374B2 (en) | 2001-08-03 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbB family members and methods of use thereof |
EP1421113A4 (en) * | 2001-08-03 | 2005-04-13 | Commw Scient Ind Res Org | Methods of screening based on the egf receptor crystal structure |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
IL161430A0 (en) * | 2001-10-19 | 2004-09-27 | Pharma Mar Sa | Pharmaceutical compositions containing ecteinascidin 743 |
US7415359B2 (en) * | 2001-11-02 | 2008-08-19 | Gene Network Sciences, Inc. | Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents |
EP1495123B1 (en) * | 2002-03-26 | 2013-10-30 | Zensun (Shanghai) Science and Technology Limited | Erbb3 based methods and compositions for treating neoplasms |
US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
WO2004000102A2 (en) * | 2002-06-19 | 2003-12-31 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
JP2006512895A (en) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | Ligand |
BRPI0408928A (en) * | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | methods to determine a disease situation in a patient, an apoptotic situation of cells in a sample, and a cancer situation in a patient |
CA2534898A1 (en) * | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
US20070059785A1 (en) * | 2003-08-15 | 2007-03-15 | Smithkline Beecham Corporation | Biomarkers in cancer |
CN100559203C (en) * | 2003-09-19 | 2009-11-11 | Nxp股份有限公司 | The electronic circuit that comprises secret submodule |
US8554486B2 (en) * | 2004-02-20 | 2013-10-08 | The Mathworks, Inc. | Method, computer program product, and apparatus for selective memory restoration of a simulation |
BRPI0508286B8 (en) * | 2004-03-31 | 2021-05-25 | Dana Farber Cancer Inst Inc | method to determine the likelihood of efficacy of an egfr tyrosine kinase inhibitor to treat cancer, use of an egfr tyrosine kinase inhibitor, probe, kit, and, primer pair |
EP1778270A4 (en) * | 2004-05-05 | 2009-09-02 | Merrimack Pharmaceuticals Inc | Bispecific binding agents for modulating biological activity |
ES2553264T3 (en) * | 2004-05-27 | 2015-12-07 | The Regents Of The University Of Colorado | Methods for predicting the clinical outcome for epidermal growth factor receptor inhibitors for cancer patients |
WO2005121380A1 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham Corporation | Predictive biomarkers in cancer therapy |
WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
RU2410438C2 (en) * | 2004-08-06 | 2011-01-27 | Дженентек, Инк. | Analyses and methods using biomarkers |
AU2005272848A1 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
US20060136139A1 (en) * | 2004-10-12 | 2006-06-22 | Elcock Adrian H | Rapid computational identification of targets |
WO2006044748A2 (en) | 2004-10-15 | 2006-04-27 | Monogram Biosciences, Inc. | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS |
GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
RU2007135216A (en) | 2005-02-23 | 2009-03-27 | Мерримак Фармасьютикалз, Инк. (Us) | BSPECIFIC BINDING AGENTS FOR MODULATION OF BIOLOGICAL ACTIVITY |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
WO2007041502A2 (en) | 2005-09-30 | 2007-04-12 | Monogram Biosciences | Methods for determining responsiveness to cancer therapy |
CA2624613A1 (en) | 2005-10-05 | 2007-04-12 | Astrazeneca Uk Limited | Method to predict or monitor the response of a patient to an erbb receptor drug |
AR056857A1 (en) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES |
US7908091B2 (en) * | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
JP2009532393A (en) | 2006-04-07 | 2009-09-10 | コペンハーゲン ユニバーシティ | ErbB receptor-derived peptide fragment |
DK2032982T3 (en) | 2006-05-05 | 2012-11-05 | Univ Yale | USE OF SUBCELLULAR LOCATION PROFILES AS PROGNOSTIC OR PREDICTIVE INDICATORS |
EP2047262A4 (en) * | 2006-07-13 | 2011-03-16 | Univ Yale | Methods for making cancer prognoses based on the subcellular localization of biomarkers |
EP2097754B2 (en) | 2006-11-28 | 2018-01-24 | Daiichi Sankyo Europe GmbH | Activated her3 as a marker for predicting therapeutic efficacy |
US7825127B2 (en) * | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
CL2008000614A1 (en) | 2007-03-02 | 2008-09-05 | Genentech Inc F Hoffmann La Ro | METHOD TO TREAT A PATIENT WITH A TYPE OF CANCER THAT EXPRESSES THE HER3 RECEIVER AT A LOW LEVEL THROUGH THE ADMINISTRATION OF AN INHIBITOR OF THE HER DIMERIZATION. |
DK2076289T3 (en) * | 2007-04-13 | 2015-02-09 | Dana Farber Cancer Inst Inc | Methods for treating cancer resistance to ErbB drugs |
US8623592B2 (en) | 2008-08-15 | 2014-01-07 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
-
2009
- 2009-08-17 US US13/058,687 patent/US8623592B2/en not_active Expired - Fee Related
- 2009-08-17 CN CN2009801404673A patent/CN102224255A/en active Pending
- 2009-08-17 KR KR1020117005954A patent/KR20110044905A/en not_active Application Discontinuation
- 2009-08-17 EA EA201100373A patent/EA022884B1/en not_active IP Right Cessation
- 2009-08-17 JP JP2011523216A patent/JP2012500008A/en active Pending
- 2009-08-17 ES ES09791584T patent/ES2433424T3/en active Active
- 2009-08-17 WO PCT/US2009/054051 patent/WO2010019952A2/en active Application Filing
- 2009-08-17 PE PE2011000159A patent/PE20120015A1/en not_active Application Discontinuation
- 2009-08-17 EP EP09791584.7A patent/EP2318548B1/en not_active Revoked
- 2009-08-17 AU AU2009281721A patent/AU2009281721A1/en not_active Abandoned
- 2009-08-17 CA CA2732658A patent/CA2732658A1/en not_active Abandoned
- 2009-08-17 UA UAA201101792A patent/UA104868C2/en unknown
- 2009-08-17 NZ NZ591137A patent/NZ591137A/en not_active IP Right Cessation
- 2009-08-17 MX MX2011001764A patent/MX2011001764A/en active IP Right Grant
- 2009-08-17 BR BRPI0917871A patent/BRPI0917871A2/en not_active IP Right Cessation
-
2010
- 2010-02-17 US US12/707,521 patent/US20110027291A1/en not_active Abandoned
-
2011
- 2011-01-25 IL IL210865A patent/IL210865A/en not_active IP Right Cessation
- 2011-02-04 ZA ZA2011/00921A patent/ZA201100921B/en unknown
- 2011-02-14 DO DO2011000054A patent/DOP2011000054A/en unknown
- 2011-02-15 SV SV2011003840A patent/SV2011003840A/en unknown
- 2011-02-16 CO CO11018669A patent/CO6341654A2/en not_active Application Discontinuation
- 2011-03-04 EC EC2011010872A patent/ECSP11010872A/en unknown
- 2011-03-10 CR CR20110128A patent/CR20110128A/en unknown
- 2011-03-11 MA MA33695A patent/MA32630B1/en unknown
- 2011-09-21 HK HK11109930.1A patent/HK1155782A1/en not_active IP Right Cessation
-
2014
- 2014-01-06 US US14/148,379 patent/US20140127238A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,664 patent/US20170307631A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997035885A1 (en) * | 1996-03-27 | 1997-10-02 | Genentech, Inc. | ErbB3 ANTIBODIES |
EP1728802A2 (en) * | 1996-03-27 | 2006-12-06 | Genentech, Inc. | ErbB3 antibodies |
WO2007015935A2 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
WO2008100624A2 (en) * | 2007-02-16 | 2008-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
Non-Patent Citations (3)
Title |
---|
ERJALA KAISA ET AL: "Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 JUL 2006, vol. 12, no. 13, 1 July 2006 (2006-07-01), pages 4103 - 4111, XP002554455, ISSN: 1078-0432 * |
SCHOEBERL BIRGIT M ET AL: "Computational modeling and simulation lead to the development of MM-121, a human monoclonal antibody ErbB3 antagonist", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 49, 1 April 2008 (2008-04-01), pages 386, XP009125511, ISSN: 0197-016X * |
SCHOEBERL BIRGIT M ET AL: "MM-121: a human monoclonal antibody ErbB3 antagonist", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 49, 1 April 2008 (2008-04-01), pages 944, XP009125512, ISSN: 0197-016X * |
Also Published As
Publication number | Publication date |
---|---|
US20170307631A1 (en) | 2017-10-26 |
DOP2011000054A (en) | 2011-04-30 |
WO2010019952A2 (en) | 2010-02-18 |
KR20110044905A (en) | 2011-05-02 |
HK1155782A1 (en) | 2012-05-25 |
IL210865A0 (en) | 2011-04-28 |
US8623592B2 (en) | 2014-01-07 |
CR20110128A (en) | 2011-09-27 |
CA2732658A1 (en) | 2010-02-18 |
ZA201100921B (en) | 2014-06-25 |
ES2433424T3 (en) | 2013-12-11 |
MA32630B1 (en) | 2011-09-01 |
EP2318548A2 (en) | 2011-05-11 |
AU2009281721A1 (en) | 2010-02-18 |
US20140127238A1 (en) | 2014-05-08 |
NZ591137A (en) | 2012-10-26 |
EP2318548B1 (en) | 2013-10-16 |
CN102224255A (en) | 2011-10-19 |
IL210865A (en) | 2014-04-30 |
SV2011003840A (en) | 2011-07-06 |
BRPI0917871A2 (en) | 2017-06-20 |
CO6341654A2 (en) | 2011-11-21 |
EA201100373A1 (en) | 2011-08-30 |
US20110159513A1 (en) | 2011-06-30 |
JP2012500008A (en) | 2012-01-05 |
US20110027291A1 (en) | 2011-02-03 |
EA022884B1 (en) | 2016-03-31 |
PE20120015A1 (en) | 2012-01-26 |
MX2011001764A (en) | 2011-05-19 |
ECSP11010872A (en) | 2011-09-30 |
UA104868C2 (en) | 2014-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010019952A3 (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
WO2019213282A8 (en) | Biomarkers for evaluating car-t cells to predict clinical outcome | |
WO2007061755A3 (en) | Systems and methods to assess one or more body fluid metrics | |
BRPI0510617A (en) | use of il-17 expression to predict skin inflammation; treatment processes | |
WO2007143211A3 (en) | Methods for identifying agents and their use for the prevention of restenosis | |
WO2007092433A3 (en) | Osteoporosis associated markers and methods of use thereof | |
WO2006125117A3 (en) | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component | |
MX2009013410A (en) | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness. | |
WO2012118750A3 (en) | Biological markers and methods for predicting response to b-cell antagonists | |
BR112013006764A2 (en) | method for assessing a patient, kit, computer readable medium, method for assessing a treatment, method for assessing a patient's risk, method for monitoring, method for diagnosing, testing system, method for classifying or grouping a population of individuals, method for assessing a surrogate outcome, method for treating, use of at least one biomarker, use of an agent | |
WO2010018601A3 (en) | Genetic variants predictive of cancer risk | |
WO2014169226A3 (en) | Methods of diagnosing and treating chronic pain | |
WO2010068794A3 (en) | Hif inhibitors and use thereof | |
EA201590630A1 (en) | METHODS OF TREATMENT AND DIAGNOSTICS ASSOCIATED WITH LYZYLOXIDE-LIKE PROTEIN 2 (LOXL2) | |
GB0711327D0 (en) | Diagnostic method | |
BR112012007555A2 (en) | biomarkers to predict the sensitivity and response of ck2 protein kinase mediated diseases to ck2 inhibitors | |
WO2012018857A3 (en) | Prediction of and monitoring cancer therapy response based on gene expression profiling | |
MX2009001070A (en) | Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma. | |
WO2012010871A3 (en) | Systems and methods for medical data processing and analysis | |
WO2009022988A3 (en) | Vhz for diagnosis and treatment of cancer | |
WO2012054915A3 (en) | Homozygous and heterozygous idh1 gene-defective human astrocytoma cell lines | |
TN2011000069A1 (en) | Methods and systems for preicting response of cells to a therapeutic agent | |
CA2699376C (en) | Gene signature for the prediction of radiation therapy response | |
WO2008012692A3 (en) | Assay for efficacy of histone deacetylase inhibitors | |
WO2013173085A3 (en) | Methods and systems for predicting jamming effectiveness |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980140467.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09791584 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2732658 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009281721 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13058687 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2011523216 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011000315 Country of ref document: CL Ref document number: 591137 Country of ref document: NZ Ref document number: 2011020254 Country of ref document: EG |
|
ENP | Entry into the national phase |
Ref document number: 0125711 Country of ref document: KE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000159-2011 Country of ref document: PE Ref document number: MX/A/2011/001764 Country of ref document: MX Ref document number: 12011500341 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11018669 Country of ref document: CO |
|
REEP | Request for entry into the european phase |
Ref document number: 2009791584 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009791584 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009281721 Country of ref document: AU Date of ref document: 20090817 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1609/CHENP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000128 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 20117005954 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201100373 Country of ref document: EA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: PI0917871 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110215 |